Synthesis and biological characterization of 3-(imidazol-1-ylmethyl)piperidine sulfonamides as aromatase inhibitors
作者:Mauro Di Matteo、Alessandra Ammazzalorso、Federico Andreoli、Irene Caffa、Barbara De Filippis、Marialuigia Fantacuzzi、Letizia Giampietro、Cristina Maccallini、Alessio Nencioni、Marco Daniele Parenti、Debora Soncini、Alberto Del Rio、Rosa Amoroso
DOI:10.1016/j.bmcl.2016.04.078
日期:2016.7
receptor positive breast cancer in post-menopausal women are aromataseinhibitors. In order to develop new aromataseinhibitors, we designed and synthesized new imidazolylmethylpiperidine sulfonamides using the structure of the previously identified aromataseinhibitor SYN 20028567 as starting lead. By this approach, three new aromataseinhibitors with IC50 values that are similar to that of letrozole and
[EN] 2-SULFONYLAMINO-4-HETEROARYL BUTYRAMIDE ANTAGONISTS OF CCR10<br/>[FR] ANTAGONISTES DE 2-SULFONYLAMINO-4-HÉTÉROARYL BUTYRAMIDE DE CCR10
申请人:BOEHRINGER INGELHEIM INT
公开号:WO2009126675A1
公开(公告)日:2009-10-15
This invention relates to a compound of formula (I) and the pharmaceutically acceptable salts thereof wherein R1, R2, R4. Ar and Het are as defined herein. The invention also relates to methods of using the compound of formula (I) to treat a diseases and disorders that are mediated or sustained through the activity of CCR10.
2-SULFONYLAMINO-4-HETEROARYL BUTYRAMIDE ANTAGONISTS OF CCR10
申请人:Abeywardane Asitha
公开号:US20110275800A1
公开(公告)日:2011-11-10
This invention relates to a compound of formula (I) and the pharmaceutically acceptable salts thereof wherein R
1
, R
2
, R
4
. Ar and Het are as defined herein. The invention also relates to methods of using the compound of formula (I) to treat a diseases and disorders that are mediated or sustained through the activity of CCR
10
.